Actively Recruiting

Age: 18Years - 100Years
MALE
NCT03474913

Upright MRI for Prostate Cancer Screening

Led by Icahn School of Medicine at Mount Sinai · Updated on 2026-01-07

550

Participants Needed

1

Research Sites

404 weeks

Total Duration

On this page

Sponsors

I

Icahn School of Medicine at Mount Sinai

Lead Sponsor

T

The Fonar Corporation

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is an investigator initiated study to test the efficacy of an upright MRI (Magnetic Resonance Imaging) for the screening of prostate cancer. The purpose of this study is to compare Upright MRI as a technique to PSA (Prostate Specific Antigen) and current MRI imaging. It will take place at Mount Sinai Hospital, and last for a total of about 5 years. Eligible patients will be determined by the urologist. The target population is men who are at risk for prostate cancer, as determined by the urologist. Diagnostic criteria will include elevated PSA and an abnormal digital rectal exam (DRE). After patients are screened and determined eligible, they will be asked to have a seated MRI using the Indomitable Magnetic Resonance Imaging Scanner, Ex vivo magnetic resonance imaging using 0.6 T strength, as well as a standard of care closed 3T MRI. After each scan, the patient will be given a series of questionnaires to assess their comfort level during the scan. Patients will be followed every 6 months after completion of (or early withdrawal from) study enrollment until 5 years.

CONDITIONS

Official Title

Upright MRI for Prostate Cancer Screening

Who Can Participate

Age: 18Years - 100Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Men at risk of prostate cancer and have been advised to have a prostate MRI.
  • Age 18 years or older.
  • Fit to undergo all study procedures including ultrasound guided biopsy.
  • Able to tolerate general or spinal anesthesia.
  • Able to understand and willing to sign informed consent and follow the study protocol.
Not Eligible

You will not qualify if you...

  • Treated with 5-alpha-reductase inhibitors at enrollment or within 6 months prior.
  • Previous prostate biopsy, prostate surgery, or prostate cancer treatment (except for benign prostatic hyperplasia or bladder obstruction treatments).
  • Evidence of urinary tract infection or acute prostatitis within the last 3 months.
  • Contraindications to MRI such as pacemaker, estimated GFR ≤50, or implanted cardiac defibrillator.
  • Any other medical condition preventing study procedures.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10029

Actively Recruiting

Loading map...

Research Team

M

Monali Fatterpekar, Ph.D.

CONTACT

C

Cristina Pasat-Karasik

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here